Organoids: A Platform Ready for Glioblastoma Precision Medicine?

Jin, Wei-Lin; Jin, Ming-Zhu; Tu, Yan-Yang

Jin, Wei-Lin; Jin, Ming-Zhu; Tu, Yan-Yang.

Afiliação

Jin WL; Center for Translational Medicine, Affiliated Hospital of Guilin Medical University, Guilin 541004, China; Institute of Nano-Biomedicine and Engineering, Department of Instrument Science and Engineering, School of Electronic Information and Electronic Engineering, Shanghai Jiao Tong University, Shanghai 200240, China. Electronic address: weilinjin@sjtu.edu.cn.
Jin MZ; Department of Gynecology and Obstetrics, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
Tu YY; Center for Translational Medicine, Affiliated Hospital of Guilin Medical University, Guilin 541004, China.

Trends Cancer ; 6(4): 265-267, 2020 04.

Article em En | MEDLINE | ID: mdl-32209439

ABSTRACT

ABSTRACT

Patient-derived organoids can recapitulate parental tumor heterogeneity. In a recent study in Cell, Jacob et al. cultivated glioblastoma organoids (GBOs) to mimic tumor heterogeneity and chimeric antigen receptor (CAR)-T cell immunotherapy, applied it for xenograft establishment and drug testing, and generated a biobank for the timely start of post-operation therapy.

Assuntos

Glioblastoma; Receptores de Antígenos Quiméricos; Humanos; Organoides; Medicina de Precisão; Linfócitos T

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Glioblastoma / Receptores de Antígenos Quiméricos Limite: Humans Idioma: En Revista: Trends Cancer Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google